(Press-News.org) BOSTON—Medications for type 2 diabetes and obesity known as GLP-1 receptor agonists may lower the risk of acute pancreatitis recurrence in people with obesity and those with type 2 diabetes, according to a study presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Doctors have been cautious about prescribing these medications in patients with a history of pancreatitis due to the potential risk of worsening the condition – a warning that is included in prescribing information, said lead researcher Mahmoud Nassar, M.D., Ph.D., Department of Medicine fellow in the Division of Endocrinology, Diabetes, and Metabolism in the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo in Buffalo, N.Y. Acute pancreatitis is a sudden inflammation of the pancreas.
“Our research highlights the safety and the potential for GLP-1 receptor agonists to reduce the risk of acute pancreatitis recurrence in individuals with obesity and type 2 diabetes, challenging previous concerns and offering new hope for effective disease management,” Nassar said.
The researchers used data from a large database called TriNetX, which contains information from about 127 million patients across 15 countries, mainly from the United States. They identified 638,501 individuals with a history of acute pancreatitis.
They focused on adults with diabetes and obesity who had been diagnosed with acute pancreatitis. The researchers wanted to see if certain medications for diabetes and obesity (specifically, GLP-1 receptor agonists, SGLT2 inhibitors and DPP4 inhibitors) affected their risk of getting pancreatitis again.
Their analysis covered a wide range of medications within each category to understand how these types of treatments might affect pancreatitis risk. They also looked closely at different patient characteristics, such as age, gender, body mass index (BMI) and blood test results, to better understand patient groups.
To figure out the risk of pancreatitis, they tracked how many patients developed pancreatitis again within 5 years of starting their medication. They compared groups of patients taking different medications, matching them by patient characteristics.
When the GLP-1 group was compared with patients taking SGLT2 inhibitors, the GLP-1 group showed a lower risk of acute pancreatitis recurrence (15.2%) compared with 24% in the SGLT2i group. When GLP-1 patients were compared with those taking DPP4i drugs, the GLP-1 group's recurrence risk was 14.4%, compared with 23.3% in the DPP4i group. When GLP-1 patients were compared with those not taking any of these medications, the GLP-1 group's recurrence risk was 14.5%, compared with 51.6% in the comparison group.
“This study provides critical insights that could change the treatment landscape for patients with obesity and type 2 diabetes, particularly those with a history of acute pancreatitis,” Nassar said. “The possibility of using GLP-1 receptor agonists more broadly offers hope for better managing these conditions, improving patient outcomes and enhancing quality of life. It emphasizes the importance of personalized medicine, where treatment decisions are tailored to the individual's specific health profile and needs.”
# # #
Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.
The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.
END
GLP-1 medications for type 2 diabetes and obesity may lower risk of acute pancreatitis
2024-06-01
ELSE PRESS RELEASES FROM THIS DATE:
Anti-obesity medication tirzepatide remains effective even for those with diabetes and other complications
2024-06-01
BOSTON—Having medical conditions linked to obesity does not impact the total weight loss achieved with the anti-obesity medication tirzepatide, according to an industry-supported study being presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Obesity causes or worsens over 200 diseases. It has been widely believed that when patients suffer multiple medical problems, they are not able to lose as much weight as those without medical issues. The new study, funded by tirzepatide maker Eli Lilly Inc., was designed to see if having more obesity-associated ...
Risk for heart attack and stroke increases in people with obesity for a decade or more
2024-06-01
BOSTON—People under age 50 have a greater risk for heart attack or stroke if they’ve lived with obesity for 10 years, according to industry-sponsored research being presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
“It is well established that people who have excess weight at any point in time have a greater risk of heart attacks and strokes. What was not known was whether it matters for how long someone has been exposed to excess weight,” said Alexander Turchin, M.D., M.S., Director of Quality at the Division of Endocrinology at Brigham & Women’s ...
Asian patients more likely to develop type 2 diabetes 1 year after prediabetes diagnosis compared to white and Black patients
2024-06-01
BOSTON—One year after a prediabetes diagnosis, Asians were more likely to develop diabetes mellitus whereas Black patients were more likely to remain in prediabetes range, highlighting racial disparities in diabetes prevention, according to data presented at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
“Every year a small proportion of patients with prediabetes will progress to diabetes mellitus with some proportion of patients reverting to normal glucose levels,” said Ewelina Niedzialkowska, M.D., an internal medicine resident at Corewell Health William Beaumont University Hospital, in Royal Oak, Mich. “While diet, lifestyle ...
Synthetic estrogen associated with increased anxiety-like behaviors in a rat model
2024-06-01
BOSTON—The type of estrogen in hormonal birth control may influence anxiety-like behaviors, according to data presented by Abigail Hegwood, M.S., from the Prakapenka Lab at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
“It is plausible that estrogen type is a key player in mood or cognitive related side effects of hormone-based contraceptive use,” said Alesia Prakapenka, Ph.D., an assistant professor in the Biomedical Sciences program at Midwestern University in Downers Grove, Ill.
According to the CDC, 12.6% of women in the United States between the ages of 15 and 49 reported using oral contraceptives from ...
Revolutionizing robotics: A breakthrough in soft actuator technology
2024-06-01
In an era where robotics are increasingly becoming a part of everyday life, a significant breakthrough has been made by a team of researchers at Zhe jiang University, China. Their latest creation, a wrist-inspired soft actuator capable of bidirectional torsion, promises to transform the landscape of soft robotics.
The innovative design of this actuator, described in detail in the journal Cyborg Bionic Systems, is inspired by the human wrist's ability to perform complex movements. Unlike traditional robotic mechanisms that rely on rigid components, this soft actuator utilizes a magneto-pneumatic hybrid system combined with a Kresling origami structure. This design allows for an astonishing ...
Huazhong University unveils breakthrough in rapid topology identification for complex networks
2024-06-01
Researchers from Huazhong University of Science and Technology, in collaboration with the Donders Institute for Brain, Cognition and Behavior at Radboud University, have developed a revolutionary method for the rapid identification of network topologies. Their new approach, detailed in a recent publication in Cyborg Bionic Systems, significantly accelerates the process of understanding complex dynamical networks, which are crucial in numerous applications ranging from power grids to transportation systems.
The innovative method, named Finite-Time Topology Identification of Delayed Complex Dynamical Networks (FT-TIDCN), leverages finite-time stability ...
Prediabetes raises Mexicans’ risk of dying prematurely of heart or kidney disease
2024-06-01
BOSTON—Prediabetes increases the risk of dying before age 75, particularly due to heart disease, kidney disease and acute diabetic complications, according to a new study presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
“Prediabetes is well known to increase the risk of developing diabetes; however, information about other complications of prediabetes in Latin America was limited before this study,” said study researcher Carlos Fermin-Martinez, M.D., of the National Autonomous University of Mexico in Mexico City, Mexico. He is also with the National Institute of Geriatrics in Mexico ...
GLP-1 has the power to change taste sensitivity in women with obesity
2024-06-01
BOSTON—Semaglutide improved taste sensitivity, changed gene expression in the tongue that’s responsible for taste perception, and changed the brain’s response to sweet tastes, according to research presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
“People with obesity often perceive tastes less ‘intensely,’ and they have an inherently elevated desire for sweet and energy-dense food,” said Mojca Jensterle Sever, Ph.D., of the University Medical Centre in Ljubljana, Slovenia.
Jensterle Sever and colleagues designed a proof-of-concept study on the impact of GLP-1 ...
Race and social vulnerability impact glycemic control in people with diabetes
2024-06-01
BOSTON—People of color and those who experience social vulnerability are more likely to experience worse glycemic control than their white counterparts, according to research presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
“As of 2021, 29.7 million people were living with diabetes, contributing to significant morbidity across the population. Despite advances in diabetic care, marginalized populations bear an increased burden of diabetic complications,” said study author Jennifer Tich, M.D., from Internal Medicine-Pediatrics R3 at the University of Rochester in Rochester, N.Y.
Tich and colleagues identified ...
Higher blood concentrations of testosterone are associated with reduced risk of developing type 2 diabetes in men under 65
2024-06-01
BOSTON—Testosterone appears protective against developing type 2 diabetes in men who are overweight or obese and under age 65, but not in men over that age, according to a study presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
“A low blood testosterone concentration is an independent risk factor for developing type 2 diabetes, and high levels of testosterone appear protective against the development of type 2 diabetes,” said lead researcher ...